135 related articles for article (PubMed ID: 15596026)
1. Tezosentan in the management of decompensated heart failure.
Cheng JW
Cardiol Rev; 2005; 13(1):28-34. PubMed ID: 15596026
[TBL] [Abstract][Full Text] [Related]
2. Tezosentan in the treatment of acute heart failure.
Tovar JM; Gums JG
Ann Pharmacother; 2003 Dec; 37(12):1877-83. PubMed ID: 14632537
[TBL] [Abstract][Full Text] [Related]
3. The dual endothelin receptor antagonist tezosentan acutely improves hemodynamic parameters in patients with advanced heart failure.
Schalcher C; Cotter G; Reisin L; Bertel O; Kobrin I; Guyene TT; Kiowski W
Am Heart J; 2001 Aug; 142(2):340-9. PubMed ID: 11479476
[TBL] [Abstract][Full Text] [Related]
4. Tezosentan in patients with acute heart failure: design of the Value of Endothelin Receptor Inhibition with Tezosentan in Acute heart failure Study (VERITAS).
Teerlink JR; McMurray JJ; Bourge RC; Cleland JG; Cotter G; Jondeau G; Krum H; Metra M; O'Connor CM; Parker JD; Torre-Amione G; Van Veldhuisen DJ; Frey A; Rainisio M; Kobrin I;
Am Heart J; 2005 Jul; 150(1):46-53. PubMed ID: 16084150
[TBL] [Abstract][Full Text] [Related]
5. Additional effects of endothelin receptor blockade and angiotensin converting enzyme inhibition in rats with chronic heart failure.
Qiu CB; Qiu CS; Hess P; Clozel JP; Clozel M
Acta Pharmacol Sin; 2001 Jun; 22(6):541-8. PubMed ID: 11747762
[TBL] [Abstract][Full Text] [Related]
6. Tezosentan. Actelion/Genentech.
Rossetti E; De Servi S
Curr Opin Investig Drugs; 2003 Mar; 4(3):323-8. PubMed ID: 12735233
[TBL] [Abstract][Full Text] [Related]
7. The hemodynamic and neurohormonal effects of low doses of tezosentan (an endothelin A/B receptor antagonist) in patients with acute heart failure.
Cotter G; Kaluski E; Stangl K; Pacher R; Richter C; Milo-Cotter O; Perchenet L; Kobrin I; Kaplan S; Rainisio M; Frey A; Neuhart E; Vered Z; Dingemanse J; Torre-Amione G
Eur J Heart Fail; 2004 Aug; 6(5):601-9. PubMed ID: 15302008
[TBL] [Abstract][Full Text] [Related]
8. Tezosentan in patients with acute heart failure and acute coronary syndromes: design of the fourth Randomized Intravenous Tezosentan Study (RITZ-4).
O'Connor CM; Gattis WA; Adams KF; Shah MR; Frey A; Gheorghiade M;
Am Heart J; 2003 Feb; 145(2 Suppl):S58-9. PubMed ID: 12594454
[No Abstract] [Full Text] [Related]
9. The development of new medical treatments for acute decompensated heart failure.
Teerlink JR
Heart Fail Monit; 2002; 2(4):129-37. PubMed ID: 12634887
[TBL] [Abstract][Full Text] [Related]
10. Cyclosporin increases the exposure to tezosentan, an intravenous dual endothelin receptor antagonist.
van Giersbergen PL; Bodin F; Dingemanse J
Eur J Clin Pharmacol; 2002 Jul; 58(4):243-5. PubMed ID: 12136369
[TBL] [Abstract][Full Text] [Related]
11. Hemodynamic and clinical effects of tezosentan, an intravenous dual endothelin receptor antagonist, in patients hospitalized for acute decompensated heart failure.
Torre-Amione G; Young JB; Colucci WS; Lewis BS; Pratt C; Cotter G; Stangl K; Elkayam U; Teerlink JR; Frey A; Rainisio M; Kobrin I
J Am Coll Cardiol; 2003 Jul; 42(1):140-7. PubMed ID: 12849674
[TBL] [Abstract][Full Text] [Related]
12. A pilot safety trial of prolonged (48 h) infusion of the dual endothelin-receptor antagonist tezosentan in patients with advanced heart failure.
Torre-Amione G; Durand JB; Nagueh S; Vooletich MT; Kobrin I; Pratt C
Chest; 2001 Aug; 120(2):460-6. PubMed ID: 11502644
[TBL] [Abstract][Full Text] [Related]
13. Effects of tezosentan on symptoms and clinical outcomes in patients with acute heart failure: the VERITAS randomized controlled trials.
McMurray JJ; Teerlink JR; Cotter G; Bourge RC; Cleland JG; Jondeau G; Krum H; Metra M; O'Connor CM; Parker JD; Torre-Amione G; van Veldhuisen DJ; Lewsey J; Frey A; Rainisio M; Kobrin I;
JAMA; 2007 Nov; 298(17):2009-19. PubMed ID: 17986694
[TBL] [Abstract][Full Text] [Related]
14. Usefulness of an elevated troponin-I in predicting clinical events in patients admitted with acute heart failure and acute coronary syndrome (from the RITZ-4 trial).
Gattis WA; O'Connor CM; Hasselblad V; Adams KF; Kobrin I; Gheorghiade M
Am J Cardiol; 2004 Jun; 93(11):1436-7, A10. PubMed ID: 15165935
[TBL] [Abstract][Full Text] [Related]
15. Pharmacology of new agents for acute heart failure syndromes.
Gheorghiade M; Teerlink JR; Mebazaa A
Am J Cardiol; 2005 Sep; 96(6A):68G-73G. PubMed ID: 16181825
[TBL] [Abstract][Full Text] [Related]
16. Tezosentan in patients with acute heart failure and acute coronary syndromes: results of the Randomized Intravenous TeZosentan Study (RITZ-4).
O'Connor CM; Gattis WA; Adams KF; Hasselblad V; Chandler B; Frey A; Kobrin I; Rainisio M; Shah MR; Teerlink J; Gheorghiade M;
J Am Coll Cardiol; 2003 May; 41(9):1452-7. PubMed ID: 12742280
[TBL] [Abstract][Full Text] [Related]
17. Tezosentan, a combined parenteral endothelin receptor antagonist, produces pulmonary vasodilation in lambs with acute and chronic pulmonary hypertension.
Fitzgerald RK; Oishi P; Ovadia B; Ross GA; Reinhartz O; Johengen MJ; Fineman JR
Pediatr Crit Care Med; 2004 Nov; 5(6):571-7. PubMed ID: 15530195
[TBL] [Abstract][Full Text] [Related]
18. The endothelin receptor antagonist tezosentan improves renal microcirculation in a porcine model of endotoxemic shock.
Fenhammar J; Andersson A; Frithiof R; Forestier J; Weitzberg E; Sollevi A; Hjelmqvist H
Acta Anaesthesiol Scand; 2008 Nov; 52(10):1385-93. PubMed ID: 19025532
[TBL] [Abstract][Full Text] [Related]
19. Hemodynamic effects of tezosentan, an intravenous dual endothelin receptor antagonist, in patients with class III to IV congestive heart failure.
Torre-Amione G; Young JB; Durand J; Bozkurt B; Mann DL; Kobrin I; Pratt CM
Circulation; 2001 Feb; 103(7):973-80. PubMed ID: 11181472
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics and pharmacodynamics of tezosentan, an intravenous dual endothelin receptor antagonist, following chronic infusion in healthy subjects.
Dingemanse J; Clozel M; van Giersbergen PL
Br J Clin Pharmacol; 2002 Apr; 53(4):355-62. PubMed ID: 11966665
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
